Woman with Alzheimer's has been taking new Lilly drug for over 3 years

Indianapolis-based Eli Lilly and Co.'s Alzheimer's drug.Patricia Bishara said she was diagnosed with Alzheimer's in 2017. In 2021, she joined the drug trial."We've been waiting for this for a long, long time," said Bishara when she heard about the FDA approving Lilly's new drug.

A mother of three and a grandmother to 11, Bishara wasn't going to let anything rob her of the memories she was to share with her family. "The earlier you go to get a diagnosis, the more probability that you can become taken care of because the drug is going to work better if you are in the early stages," said Bishara.The 79-year-old said every month for more than three years, she received 41 infusions.Every third or fourth month, doctors would also give her a PET scan, along with a psychological evaluation.

"It was worth being in the study for me. To help me and hopefully millions of other people now that they'll have this opportunity to get this drug and it'll help them for sure, I feel," said Bishara.Bishara said since she caught her Alzheimer's early and was able to get on the drug, her life hasn't changed much since the diagnosis.

"I'm able to drive still. I play cards. I go to church regularly; I can drive myself there. I go out with friends. I go to the movies. I live a pretty normal life," she said.

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Source: KSLcom - 🏆 549. / 51 Read more »

Lilly's Alzheimer's drug faces delayed reckoningFDA advisers will review an antibody from Eli Lilly that's been held up by safety and efficacy concerns.
Source: axios - 🏆 302. / 63 Read more »

FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Source: CNBC - 🏆 12. / 72 Read more »

FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Source: NBCNewYork - 🏆 270. / 63 Read more »

Lilly's Alzheimer’s drug that can slow disease gets backing from FDA advisersThe Associated Press
Source: NBCNews - 🏆 10. / 86 Read more »

FDA advisors recommend Eli Lilly Alzheimer’s drug that slows diseaseEli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
Source: dcexaminer - 🏆 6. / 94 Read more »